All Stories

  1. Establishment of international autoantibody reference standards for the detection of autoantibodies directed against PML bodies, GW bodies, and NuMA protein
  2. Ribavirin induces widespread accumulation of IMP dehydrogenase into rods/rings structures in multiple major mouse organs
  3. Emerging microRNAs in cancer diagnosis, progression, and immune surveillance
  4. Immune Response-Dependent Assembly of IMP Dehydrogenase Filaments
  5. Enoxacin and bis-enoxacin stimulate 4T1 murine breast cancer cells to release extracellular vesicles that inhibit osteoclastogenesis
  6. CIP2A immunosensor comprised of vertically-aligned carbon nanotube interdigitated electrodes towards point-of-care oral cancer screening
  7. Clarification Needed Regarding Anti-Topoisomerase I as a Biomarker for Non-Small Cell Lung Cancer
  8. Prescription medication use and antinuclear antibodies in the United States, 1999–2004
  9. International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I
  10. International Consensus on Antinuclear Antibody Patterns: defining negative results and reporting unidentified patterns
  11. CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma
  12. Reference standards for the detection of anti-mitochondrial and anti-rods/rings autoantibodies
  13. Antinuclear antibodies and mortality in the National Health and Nutrition Examination Survey (1999-2004)
  14. Aneurysm-Specific miR-221 and miR-146a Participates in Human Thoracic and Abdominal Aortic Aneurysms
  15. Differential capacity of therapeutic drugs to induce Rods/Rings structures in vitro and in vivo and generation of anti-Rods/Rings autoantibodies
  16. MicroRNA-375 as a biomarker for malignant transformation in oral lesions
  17. Anti-rods/rings autoantibody seropositivity does not affect response to telaprevir treatment for chronic hepatitis C infection
  18. Loukoumasomes Are Distinct Subcellular Structures from Rods and Rings and Are Structurally Associated with MAP2 and the Nuclear Envelope in Retinal Cells
  19. Biomarkers and Pathogenic Mechanisms in Autoimmunity
  20. Dr Eng M. Tan: a tribute to an enduring legacy in autoimmunity
  21. Periodontal bacterial colonization in synovial tissues exacerbates collagen-induced arthritis in B10.RIII mice
  22. ‘Rod and ring’ formation from IMP dehydrogenase is regulated through the one-carbon metabolic pathway
  23. A re-evaluation of anti-NA-14 antibodies in patients with primary Sjögren’s syndrome: Significant role of interferon-γ in the production of autoantibodies against NA-14
  24. I have been working with the ICAP group to reach a consensus in the interpretation of ANA patterns.
  25. From autoantibody research to standardized diagnostic assays in the management of human diseases – report of the 12th Dresden Symposium on Autoantibodies
  26. Single-cell antibody nanowells: a novel technology in detecting anti-SSA/Ro60- and anti-SSB/La autoantibody-producing cells in peripheral blood of rheumatic disease patients
  27. Associations Between Selected Xenobiotics and Antinuclear Antibodies in the National Health and Nutrition Examination Survey, 1999–2004
  28. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results
  29. Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy
  30. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy
  31. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015
  32. Assembly of IMPDH2-Based, CTPS-Based, and Mixed Rod/Ring Structures Is Dependent on Cell Type and Conditions of Induction
  33. The Uses and Misuses of Multiplex Autoantibody Assays in Systemic Autoimmune Rheumatic Diseases
  34. Interleukin 1�-Responsive MicroRNA-146a Is Critical for the Cytokine-Induced Tolerance and Cross-Tolerance to Toll-Like Receptor Ligands
  35. Our Journey from the Study of Human Autoantibodies to the microRNA World
  36. Anti-Rods/Rings: A Human Model of Drug-Induced Autoantibody Generation
  37. miR-494 represses HOXA10 expression and inhibits cell proliferation in oral cancer
  38. CIP2A regulates cancer metabolism and CREB phosphorylation in non-small cell lung cancer
  39. Microinjection of specific anti-IMPDH2 antibodies induces disassembly of cytoplasmic rods/rings that are primarily stationary and stable structures
  40. Reproductive and Hormonal Risk Factors for Antinuclear Antibodies (ANA) in a Representative Sample of U.S. Women
  41. Autoantibodies to the Rpp25 Component of the Th/To Complex are the Most Common Antibodies in Patients with Systemic Sclerosis without Antibodies Detectable by Widely Available Commercial Tests
  42. Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α
  43. Glutamine deprivation initiates reversible assembly of mammalian rods and rings
  44. Elevated signal transducers and activators of transcription 1 correlates with increased C-C motif chemokine ligand 2 and C-X-C motif chemokine 10 levels in peripheral blood of patients with systemic lupus erythematosus
  45. Molecular Cell Biology and Immunobiology of Mammalian Rod/Ring Structures
  46. Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset
  47. miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3ζ
  48. Positive Correlation of STAT1 and miR-146a with Anemia in Patients with Systemic Lupus Erythematosus
  49. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies
  50. Antinuclear Antibody Test: When to Order?
  51. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA–mRNA interactions
  52. Regulation of TLR2-Mediated Tolerance and Cross-Tolerance through IRAK4 Modulation by miR-132 and miR-212
  53. MicroRNA-146a in autoimmunity and innate immune responses
  54. MicroRNAs and autoimmunity
  55. An SNP in the Trinucleotide Repeat Region of the TNRC6A Gene Maps to a Major TNGW1 Autoepitope in Patients with Autoantibodies to GW182
  56. Autoantibodies to Argonaute 2 (Su Antigen)
  57. Function of GW182 and GW Bodies in siRNA and miRNA Pathways
  58. Introduction: The GW Body Story as an Example of Autoantibodies with Significant Impacts to Molecular Cell Biology
  59. Reflections on Ten Years of History of, and Future Prospects for, GW182 and GW/P Body Research
  60. Relationship of Other Cytoplasmic Ribonucleoprotein Bodies (cRNPB) to GW/P Bodies
  61. The Discovery of GW Bodies
  62. Differential Reactivity to IMPDH2 by Anti-rods/rings Autoantibodies and Unresponsiveness to Pegylated Interferon-alpha/Ribavirin Therapy in US and Italian HCV Patients
  63. Defining a new role of GW182 in maintaining miRNA stability
  64. Longitudinal Study of a Human Drug-Induced Model of Autoantibody to Cytoplasmic Rods/Rings following HCV Therapy with Ribavirin and Interferon-α
  65. Keratinization-associated miR-7 and miR-21 Regulate Tumor Suppressor Reversion-inducing Cysteine-rich Protein with Kazal Motifs (RECK) in Oral Cancer
  66. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States
  67. A new immunoprecipitation-real time quantitative PCR assay for anti-Th/To and anti-U3RNP antibody detection in systemic sclerosis
  68. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis
  69. Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis
  70. Role of environmental factors in autoantibody production - importance of a detailed analysis in a small cohort
  71. Induction of Cytoplasmic Rods and Rings Structures by Inhibition of the CTP and GTP Synthetic Pathway in Mammalian Cells
  72. High resolution of microRNA signatures in human whole saliva
  73. Common Pathways of Autoimmune Inflammatory Myopathies and Genetic Neuromuscular Disorders
  74. Coexistence of anti-RNA polymerase III and anti-U1RNP antibodies in patients with systemic lupus erythematosus: two cases without features of scleroderma
  75. A secretagogue-small interfering RNA conjugate confers resistance to cytotoxicity in a cell model of Sjögren's syndrome
  76. MicroRNA in TLR signaling and endotoxin tolerance
  77. Autoantibodies to survival of motor neuron complex in patients with polymyositis: Immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins
  78. Altered miR-146a expression in Sjögren's syndrome and its functional role in innate immunity
  79. MicroRNAs in rheumatoid arthritis
  80. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies
  81. Lupus T cells switched on by DNA hypomethylation via microRNA?
  82. Polyclonal hypergammaglobulinemia and autoantibody production induced by vaccination in farmed Atlantic salmon
  83. Polymicrobial Infection with Periodontal Pathogens Specifically Enhances MicroRNA miR-146a in ApoE−/−Mice during Experimental Periodontal Disease
  84. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C
  85. Atypical clinical presentation of a subset of patients with anti-RNA polymerase III - non-scleroderma cases associated with dominant RNA polymerase i reactivity and nucleolar staining
  86. Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study
  87. Mapping of Ago2–GW182 Functional Interactions
  88. MicroRNAs in systemic rheumatic diseases
  89. Mechanistic Role of MicroRNA-146a in Endotoxin-Induced Differential Cross-Regulation of TLR Signaling
  90. Divergent GW182 functional domains in the regulation of translational silencing
  91. CIP2A expression and localization in oral carcinoma and dysplasia
  92. Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS)
  93. Anti-Th/To Are Common Antinucleolar Autoantibodies in Italian Patients with Scleroderma
  94. Overexpression of dicer as a result of reduced let-7 MicroRNA levels contributes to increased cell proliferation of oral cancer cells
  95. Life stress, negative mood states, and antibodies to heat shock protein 70 in endometrial cancer
  96. High prevalence of autoantibodies to RNA helicase A in Mexican patients with systemic lupus erythematosus
  97. Formation of GW/P bodies as marker for microRNA-mediated regulation of innate immune signaling in THP-1 cells
  98. Citrulline Dependence of Anti-Cyclic Citrullinated Peptide Antibodies in Systemic Lupus Erythematosus as a Marker of Deforming/Erosive Arthritis
  99. miR-146a Is Critical for Endotoxin-induced Tolerance
  100. Identification of Enoxacin as an Inhibitor of Osteoclast Formation and Bone Resorption by Structure-Based Virtual Screening
  101. Congenital Heart Block Not Associated with Anti-Ro/La Antibodies: Comparison with Anti-Ro/La-positive Cases
  102. MicroRNA in autoimmunity and autoimmune diseases
  103. Optimization of immunoprecipitation–western blot analysis in detecting GW182-associated components of GW/P bodies
  104. Contrast in aberrant microRNA expression in systemic lupus erythematosus and rheumatoid arthritis: Is microRNA-146 all we need?
  105. The C-terminal half of human Ago2 binds to multiple GW-rich regions of GW182 and requires GW182 to mediate silencing
  106. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases
  107. Antibody Reactivity to α-Enolase in Mothers of Children with Congenital Heart Block
  108. Co-clustering of Golgi complex and other cytoplasmic organelles to crescentic region of half-moon nuclei during apoptosis
  109. Reduced IgG anti-small nuclear ribonucleoprotein autoantibody production in systemic lupus erythematosus patients with positive IgM anti-cytomegalovirus antibodies
  110. Identification of GW182 and its novel isoform TNGW1 as translational repressors in Ago2-mediated silencing
  111. MicroRNAs and Their Emerging Roles in Immunology
  112. Inflammatory caspases are critical for enhanced cell death in the target tissue of Sjögren's syndrome before disease onset
  113. Vaccination-Induced Systemic Autoimmunity in Farmed Atlantic Salmon
  114. Differential Anti-Golgi Complex Autoantibody Production Following Murine Lactate Dehydrogenase-Elevating Virus Infection
  115. Patients with pulmonary tuberculosis are frequently positive for anti–cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide
  116. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients
  117. Clinical and serological features of patients with autoantibodies to GW/P bodies
  118. Markers of mRNA stabilization and degradation, and RNAi within astrocytoma GW bodies
  119. AutoAbSC.Org — Autoantibody Standardization Committee in 2006
  120. Clinical implication of autoantibodies in patients with systemic rheumatic diseases
  121. Small Interfering RNA-mediated Silencing Induces Target-dependent Assembly of GW/P Bodies
  122. CIP2A Inhibits PP2A in Human Malignancies
  123. The role of GW/P-bodies in RNA processing and silencing
  124. Pol I Transcription and Pre-rRNA Processing Are Coordinated in a Transcription-dependent Manner in Mammalian Cells
  125. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma
  126. Autoantibodies to RNA helicase A: A new serologic marker of early lupus
  127. GOLGI COMPLEX AND ENDOSOME ANTIBODIES
  128. GW BODIES, P BODIES AND COMPONENTS OF THE miRNA PATHWAY
  129. Detection of the argonaute protein Ago2 and microRNAs in the RNA induced silencing complex (RISC) using a monoclonal antibody
  130. Formation of GW bodies is a consequence of microRNA genesis
  131. Molecular Dynamics Simulation of Thermal Cycling Test in Electronic Packaging
  132. GW Bodies, MicroRNAs and the Cell Cycle
  133. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti–RNA polymerase I/III antibodies
  134. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis
  135. Disruption of GW bodies impairs mammalian RNA interference
  136. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection
  137. Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects
  138. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens
  139. Unique and shared features of Golgi complex autoantigens
  140. GW182 is critical for the stability of GW bodies expressed during the cell cycle and cell proliferation
  141. Relationship of maternal autoimmune response to clinical manifestations in children with congenital complete heart block
  142. Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies
  143. Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182
  144. The GW182 protein colocalizes with mRNA degradation associated proteins hDcp1 and hLSm4 in cytoplasmic GW bodies
  145. Does the cellular localization of antigens in or on apoptotic blebs influence the pathogenicity or benefit of cognate antibodies? Comment on the article by Dieudé et al
  146. A Panel of Monoclonal Antibodies to Cytoplasmic GW Bodies and the mRNA Binding Protein GW182
  147. Interaction with GM130 during HERG Ion Channel Trafficking
  148. The La RNA-binding Protein Interacts with the Vault RNA and Is a Vault-associated Protein
  149. Cardiac 5-HT4 Serotoninergic Receptors, 52kD SSA/Ro and Autoimmune-Associated Congenital Heart Block
  150. Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer
  151. A Phosphorylated Cytoplasmic Autoantigen, GW182, Associates with a Unique Population of Human mRNAs within Novel Cytoplasmic Speckles
  152. Autoantibody to hLSm4 and the heptameric LSm complex in anti-Sm sera
  153. Leucine zipper domain of 52 kDa SS-A/Ro promotes protein dimer formation and inhibits in vitro transcription activity
  154. The GM130 and GRASP65 Golgi proteins cycle through and define a subdomain of the intermediate compartment
  155. AU Binding Proteins Recruit the Exosome to Degrade ARE-Containing mRNAs
  156. Transcription Activating Property of Autoantigen SG2NA and Modulating Effect of WD-40 Repeats
  157. SS-56, a novel cellular target of autoantibody responses in Sjögren syndrome and systemic lupus erythematosus
  158. Aberrant Expression of Fetal RNA-Binding Protein p62 in Liver Cancer and Liver Cirrhosis
  159. Interaction between 52 kDa SSA/Ro and deubiquitinating enzyme UnpEL: a clue to function
  160. Identification and Characterization of a Family of Rab11-interacting Proteins
  161. Autoimmune Responses to mRNA Binding Proteins p62 and Koc in Diverse Malignancies
  162. Residual Cajal bodies in coilin knockout mice fail to recruit Sm snRNPs and SMN, the spinal muscular atrophy gene product
  163. Membrane Trafficking Machinery Components Associated with the Mammalian Acrosome during Spermiogenesis
  164. De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma
  165. Anti-SSA/Ro and Anti-SSB/La Autoantibodies Bind the Surface of Apoptotic Fetal Cardiocytes and Promote Secretion of TNF-α by Macrophages
  166. Vesicular Traffic and Golgi Apparatus Dynamics During Mammalian Spermatogenesis: Implications for Acrosome Architecture1
  167. Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions
  168. Structure and Characterization of the Murine p80 Coilin Gene, Coil
  169. The Golgi Apparatus Segregates from the Lysosomal/Acrosomal Vesicle during Rhesus Spermiogenesis: Structural Alterations
  170. Human Autoantibodies to a Novel Golgi Protein Golgin-67: High Similarity With Golgin-95/gm 130 Autoantigen
  171. Identification and Characterization of a Novel Golgi Protein, Golgin-67
  172. Defining a novel 75-kDa phosphoprotein associated with SS-A/Ro and identification of distinct human autoantibodies
  173. A Novel Cytoplasmic Protein with RNA-binding Motifs Is an Autoantigen in Human Hepatocellular Carcinoma
  174. mRNA and Protein Expression of SSA/Ro and SSB/La in Human Fetal Cardiac Myocytes Cultured Using a Novel Application of the Langendorff Procedure
  175. Genetic and Physical Mapping of theLpsLocus: Identification of the Toll-4 Receptor as a Candidate Gene in the Critical Region
  176. Molecular remedy of complex I defects: Rotenone-insensitive internal NADH-quinone oxidoreductase of Saccharomyces cerevisiae mitochondria restores the NADH oxidase activity of complex I-deficient mammalian cells
  177. Molecular definition of heterogeneous nuclear ribonucleoprotein R (hnRNP R) using autoimmune antibody: Immunological relationship with hnRNP P
  178. Molecular cloning of a novel 97-kd Golgi complex autoantigen associated with Sjögren's syndrome
  179. Diversity of antinucelar antibody responses in hepatocellular carcinoma
  180. Heterochromatin protein HP1 Hsβ (p25β) and its localization with centromeres in mitosis
  181. The 52-kd protein as a target of intermolecular spreading of the immune response to components of the SS-A/Ro-SS-B/La complex
  182. Cardiac expression of 52β, an alternative transcript of the congenital heart block-associated 52-kd SS-A/Ro autoantigen, is maximal during fetal development
  183. Molecular Cloning of the RNA Polymerase I Transcription Factor hUBF/NOR-90 (UBTF) Gene and Localization to 17q21.3 by Fluorescencein SituHybridization and Radiation Hybrid Mapping
  184. Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency
  185. 17-β-Estradiol Increases Expression of 52-kDa and 60-kDa SS-A/Ro Autoantigens in Human Keratinocytes and Breast Cancer Cell Line MCF-7
  186. Simplifying 5′RACE in the hunt for full-length cDNAs
  187. Two major autoantigen—Antibody systems of the mitotic spindle apparatus
  188. Comparison of protocols for depleting anti-E. coli antibody in immunoblotting of recombinant antigens
  189. Biographical sketch and scientific contributions of Eng M. Tan
  190. Cloning and expression of mouse 60 kDa ribonucleoprotein SS-A/Ro
  191. Foreword
  192. Molecular Characterization of Golgin-245, a Novel Golgi Complex Protein Containing a Granin Signature
  193. 52-kD SS-A/Ro: genomic structure and identification of an alternatively spliced transcript encoding a novel leucine zipper-minus autoantigen expressed in fetal and adult heart
  194. A Cell-Cycle Nuclear Autoantigen Containing Wd-40 Motifs Expressed Mainly in S and G2-Phase Cells
  195. A microscale method for depleting cross-reactive anti-antibodies used in indirect immunofluorescence microscopy
  196. Human 60-kDa SS-A/Ro Ribonucleoprotein Autoantigen Gene (SSA2) Localized to 1q31 by Fluorescence in Situ Hybridization
  197. Is the Coiled Body Involved in Nucleolar Functions?
  198. Immunocytochemical characterization of human NOR-90 (upstream binding factor) and associated antigens reactive with autoimmune sera
  199. Structure, expression and chromosomal localization of human p80-coilin gene
  200. Isolated congenital heart block. long-term outcome of mothers and characterization of the immune response to ss-a/ro and to ss-b/la
  201. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma.
  202. Characterization of Antinuclear Autoantibodies Present in the Serum from Nonobese Diabetic (NOD) Mice
  203. Molecular characterization of two human autoantigens: unique cDNAs encoding 95- and 160-kD proteins of a putative family in the Golgi complex
  204. Immunocytochemical analysis of the coiled body in the cell cycle and during cell proliferation.
  205. Autoantibodies in Viral Hepatitis-Related Hepatocellular Carcinoma
  206. Human autoantibody to RNA polymerase I transcription factor hUBF. Molecular identity of nucleolus organizer region autoantigen NOR-90 and ribosomal RNA transcription upstream binding factor
  207. Immunological and ultrastructural studies of the nuclear coiled body with autoimmune antibodies
  208. Human autoantibody to a novel protein of the nuclear coiled body: immunological characterization and cDNA cloning of p80-coilin
  209. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex
  210. Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen.
  211. Association between the nucleolus and the coiled body
  212. In vitro posttranslational modification of lamin B cloned from a human T-cell line.
  213. Effective separation of the 52 kDa SSA/Ro polypeptide from the 48 kDa SSB/La polypeptide by altering conditions of polyacrylamide gel electrophoresis
  214. Sjögren's syndrome nuclear antigen B (La): cDNA cloning, structural domains, and autoepitopes
  215. Viral genomes in lymphomas of patients with Sjögren's Syndrome
  216. Ribonucleoprotein SS-B/La belongs to a protein family with consensus sequences for RNA-binding
  217. A 52-kD protein is a novel component of the SS-A/Ro antigenic particle
  218. Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity
  219. Human autoantibody-reactive epitopes of SS-B/La are highly conserved in comparison with epitopes recognized by murine monoclonal antibodies
  220. The small nuclear ribonucleoprotein SS-B/La binds RNA with a conserved protease-resistant domain of 28 kilodaltons.
  221. Monoclonal autoantibodies to nuclear antigens from murine graft-versus-host disease
  222. An immunoassay differentiating sera with antibodies to sm alone, antibodies to sm/RNP complex, and antibodies to RNP alone
  223. Antibodies against small nuclear ribonucleoproteins immunoprecipitate complexes containing ts110 moloney murine sarcoma virus genomic and messenger RNAs
  224. Effect of Cationic Proteins on the Glomerular Deposition of Anionic Proteins and Immune Complexes
  225. Characterization and purification of lupus antigen La, and RNA-binding protein.
  226. Preparation of covalently linked immune complexes of specific composition